
|Articles|September 28, 2012
Bayer Wins Early US Approval for Colon Cancer Drug
Advertisement
The U.S. Food and Drug Administration on Thursday approved a new drug for advanced colon cancer developed by Bayer AG, a month ahead of the agency's expected action date for a decision.
The drug, to be sold under the brand name Stivarga, was approved to treat colon cancer that has progressed after prior treatment or that has spread to other parts of the body, the agency said.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
4
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
5









































